Clinical trial
Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung…
NCT00003666 · Alliance for Clinical Trials in Oncology, Other · Completed
Key facts
| NCT number | NCT00003666 |
|---|---|
| Title | Irofulven in Treating Patients With Relapsed or Refractory Non-small Cell Lung Cancer |
| Official title | Phase II Trial of 6-Hydroxymethylacylfulvene (HMAF; MGI-114) in Patients With Relapsed or Refractory Non-Small Cell Lung Cancer |
| Lead sponsor | Alliance for Clinical Trials in Oncology, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | 6-hydroxymethylacylfulvene |
| Enrollment | 36 |
| Start date | Nov 1, 1998 |
| Primary completion | Sep 1, 2004 |
| Completion | Jan 1, 2006 |
| First posted | Sep 13, 2004 |
| Last update posted | Jul 20, 2016 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: